Skip to main content

Clinical trial BGB-3111-306

A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Organ Non-Hodgkin lymphoma
Trial status Trial open for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor BeiGene
EudraCT Identifier 2019-000413-36
Inclusion criteria MCL; 70 years or 65 years with co-morbidities that contraindicate autograft; ECOG 2
Last update